Edarbi and Flushing aggravated - a phase IV clinical study of FDA data


Flushing aggravated is reported only by a few people who take Edarbi.

The phase IV clinical study analyzes which people take Edarbi and have Flushing aggravated. It is created by eHealthMe based on reports of 335 people who have side effects while taking Edarbi from the FDA, and is updated regularly.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.

On Jun, 30, 2022

335 people reported to have side effects when taking Edarbi.
Among them, 3 people (0.9%) have Flushing aggravated.

What is Edarbi?

Edarbi has active ingredients of azilsartan medoxomil. It is often used in high blood pressure. eHealthMe is studying from 385 Edarbi users for its effectiveness, alternative drugs and more.

What is Flushing aggravated?

Flushing aggravated (worse the warm, red condition of human skin) is found to be associated with 621 drugs and 290 conditions by eHealthMe.

Number of Edarbi and Flushing aggravated reports submitted per year:

Could Edarbi cause Flushing aggravated?

Gender of people who have Flushing aggravated when taking Edarbi *:

  • female: 66.67 %
  • male: 33.33 %

Age of people who have Flushing aggravated when taking Edarbi *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 100 %

Common drugs people take besides Edarbi *:

  1. Tecfidera: 2 people, 66.67%
  2. Wellbutrin: 1 person, 33.33%
  3. Premarin: 1 person, 33.33%
  4. Folic Acid: 1 person, 33.33%
  5. Cymbalta: 1 person, 33.33%
  6. Calcium: 1 person, 33.33%
  7. Bystolic: 1 person, 33.33%
  8. Baclofen: 1 person, 33.33%

Common side effects people have besides Flushing aggravated *:

  1. Weakness: 1 person, 33.33%
  2. Rashes (redness): 1 person, 33.33%
  3. Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 1 person, 33.33%
  4. Itching: 1 person, 33.33%
  5. Insomnia (sleeplessness): 1 person, 33.33%
  6. Feeling Hot: 1 person, 33.33%
  7. Feeling Abnormal: 1 person, 33.33%
  8. Abdominal Discomfort: 1 person, 33.33%

Common conditions people have *:

  1. Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 2 people, 66.67%
  2. High Density Lipoprotein Decreased: 1 person, 33.33%

* Approximation only. Some reports may have incomplete information.

Do you take Edarbi and have Flushing aggravated?

Check whether Flushing aggravated is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Alternative drugs to, pros and cons of Edarbi:

Flushing aggravated treatments and more:

COVID vaccines that are related to Flushing aggravated:

How severe was Flushing aggravated and when was it recovered:

Expand to all the drugs that have ingredients of azilsartan medoxomil:

Common drugs associated with Flushing aggravated:

All the drugs that are associated with Flushing aggravated:

Common conditions associated with Flushing aggravated:

All the conditions that are associated with Flushing aggravated:

How the study uses the data?

The study uses data from the FDA. It is based on azilsartan medoxomil (the active ingredients of Edarbi) and Edarbi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: